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CHARACTERIZING PLASMIN-INDUCED LAG PHASE AND APPLICATION 
OF PDMS MICROFLUIDICS TO DETECTION OF FIBRINOLYTIC ACTIVITY 
NAVEED GHANI 
ABSTRACT 
 Physical trauma is responsible for over six million deaths annually, and of these 
roughly 40 percent result from acute traumatic coagulopathy (ATC) occurring in the first 
few hours of incidence. Patients who have developed ATC have significantly improved 
survivability when treated with tranexamic acid (TXA), a chemical inhibitor of the clot 
lysing enzyme plasmin. Current methods of detecting ATC are inadequate, lacking in 
either efficient speed, sensitivity, or cost. Hyperfibrinolysis (HF) is a key component of 
ATC and can be a result of excess plasmin activity. The following study observes effects 
of plasmin on hemostasis, and explores the use of silicon-based polydimethylsiloxane 
(PDMS) microfluidics measuring changes in electrical resistance as a method to detect 
HF. 
 Coagulation was characterized by measuring turbidity of solutions containing 
fibrinogen and thrombin, and plasmin was incorporated to observe fibrinolysis and other 
plasmin-induced effects. It was found that high concentrations of plasmin caused a delay 
in the turbidity increase during coagulation. This lag phase may be a contributing factor 
to HF and ultimately ATC. 
 Finally, the use of PDMS microfluidics to measure changes in electrical resistance 
to detect coagulation and fibrinolysis activity was supported. Resistance change adhered 
closely to traditional substrate-enzyme kinetics and plasmin-induced effects mimicked 
		 v 
those which were observed in turbidity measurements. Further investment and 
development of this method of measurement could provide a faster, more accurate, and 
more inexpensive alternative to current techniques for measuring fibrinolysis.   
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INTRODUCTION 
There exists a complex balance between the formation of a fibrin clot 
(coagulation) and the degradation of that clot (fibrinolysis). This balance between 
coagulation and fibrinolysis is essential to life as it both prevents excessive hemorrhage 
upon blood vessel injury and at the same time allows clots to be degraded in an 
appropriate window of time so as to not interfere with regular blood flow. An imbalance 
in this system, known as a coagulopathy, can either be thrombotic if coagulation is 
dominant or hemorrhagic if fibrinolysis is dominant. Hemorrhagic coagulopathy 
following physical trauma has been well-documented1,2 and is commonly referred to as 
acute traumatic coagulopathy (ATC). Physical trauma is responsible for over six million 
deaths annually, and of these roughly forty percent result from ATC and occur within the 
first several hours of the trauma incidence3. ATC is one of the major causes of mortality 
among trauma patients, and hyperfibrinolysis (HF) is believed to be a central component 
of this hemostatic abnormality4. In fact, studies have shown that the presence of ATC was 
a better indicator of mortality than the Injury Severity Score (ISS), an established clinical 
score used to assess severity of trauma1,2. 
The balance of coagulation and fibrinolysis can be better understood by 
addressing the individual proteins involved. Fibrinogen, also known as factor I, is a 
plasma glycoprotein common in vertebrates. A molecule of fibrinogen is a 45 nm 
elongated structure with a D-region on either end connected to a central E-region. In total 
the molecule consists of two sets each of three polypeptide chains: A-alpha, B-beta, and 
gamma. These polypeptide chains are joined together by disulfide bridges at their N-
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terminals found in the E-region5. From the N-terminus of the A-alpha chain, the enzyme 
thrombin cleaves several peptides (fibrinopeptide A) off to expose the alpha-chain motif 
(Gly-Pro-Arg) known as knob-A. Knob-A is complementary to a site found in the D-
region known as hole-a. Similarly, thrombin cleaves N-terminal peptides from the B-beta 
chain (fibrinopeptide B) to expose the beta-chain motif (Gly-His-Arg-Pro) known as 
knob-B, which is complementary to hole-b found in the D-region of the molecule. The 
cleavage of these different fibrinopeptides by thrombin are not equivalent in rate or 
favorability, but rather depend on certain conditions such as fibrinogen attachment and 
conformation6. 
           This newly cleaved molecule, a fibrin monomer, can spontaneously assemble with 
other fibrin molecules through knob-hole interactions. Again, the A:a knob-hole 
interaction differs from that of the B:b knob-hole. The B:b interaction has relatively low 
affinity compared to the strong and stable interaction of A:a7. The fibrin monomers self-
assemble into a two-stranded, half-staggered conformation known as a protofibril. 
Between two opposite strands, the D-regions and E-regions are adjacent. Within the same 
strand, the D-regions are positioned adjacently end-to-end8. A protofibril, upon reaching 
500 to 600 nm in length, begins to aggregate laterally with other protofibrils to form 
fibers9. The manner in which protofibrils aggregate with each other and how these fibers 
further aggregate is not fully understood. Two fibrin clots can differ in their fiber 
thickness, density, branching, and overall stability due to factors that are unclear. During 
and following polymerization, however, the fibrin molecules are ligated (also known as 
crosslinked) at their D-regions by factor XIIIa. This dense covalent bonding within and 
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between fibers makes the polymerization irreversible and greatly increases stability of the 
molecule, making it more resistant to mechanical strain and chemical lysis6. It also causes 
the fiber to become insoluble10 and thus detectable by light scattering in vitro. This “lag 
phase”, between the time thrombin is introduced to fibrinogen and when protofibrils 
begin to aggregate, might be relevant to the HF observed in ATC11.        
           After the fibrin clot has formed and hemorrhage has been impeded, the clot has to 
be broken down so that it does not interfere with regular blood flow. Plasmin is the active 
enzyme primarily responsible for the degradation of the fibrin clot. It’s precursor, 
plasminogen, is released by the liver and can be activated by a variety of enzymes such as 
tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), factor XII, or 
kallikrein. These activators are also controlled by their own inhibitors, for example 
plasminogen activator inhibitor 1 (PAI-1). Plasminogen circulates in a closed 
conformation and is only susceptible to activation upon binding to fibrin clots or a cell 
surface. Once active, plasmin can cleave fibrin polymers at several different sites. This 
cleavage results in the production of cross-linked D-dimers and other fibrin degradation 
products (FDPs). Plasmin can be inactivated by different proteins such as α2-
macroglobulin and antiplasmin, which themselves are found as precursors circulating in 
plasma and activated by hemostatic cascades12. Clearly there is a delicate balance of 
plasminogen activation into plasmin, as there are activators, inhibitors, inhibitors to the 
activators, and still further factors that affect fibrinolysis activity. 
           It has been observed in this study that the presence of high concentrations of 
plasmin in a purified protein system causes an extended lag phase during fibrin 
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polymerization. In theory, there are several explanations for why plasmin levels might be 
elevated in some patients following physical trauma. Primarily, damaged endothelium 
releases tPA into circulation to activate plasminogen. This can be further exacerbated by 
trauma-related impaired hepatic clearance, allowing the plasma levels of tPA to remain 
elevated13. 
The difficulty, however, is in determining which patients have developed ATC 
and require specific treatment with tranexamic acid (TXA), a chemical inhibitor of 
plasmin. Patients with ATC are eight times more likely to suffer lethality, are more likely 
to require a massive transfusion, and require longer hospital stays than those patients who 
did not develop ATC4.  If TXA is given to patients not experiencing HF, however, they 
could experience life-threatening thrombotic activity. Traditionally, HF can be detected 
by several different techniques, but each has its weakness for application in trauma 
patients. One technique is to quantitate biomarkers of fibrinolytic events such as D-
dimers or other FDPs, plasmin-antiplasmin (PAP) complexes, or tPA complexes by 
ELISA. However this assay requires roughly 4 hours to process and is a static 
measurement of prior fibrinolytic events rather than ongoing conditions. It is also not 
particularly useful in detecting ATC since the biomarker levels tend to rise in all trauma 
patients, not just those with specific HF14. Viscoelastic tests such as rotational 
thromboelastometry (ROTEM) or thromboelastography (TEG) are more rapid, but the 
machines required to run these tests are large and expensive15. So not only would they be 
unavailable in low resource areas, but they often require a specialized lab that would have 
to receive the patient sample, run the test, and then return the results, again introducing 
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the issue of time delay14. They are also lacking in sensitivity compared to traditional 
coagulation measurements such as thrombin time, prothrombin time, and activated partial 
thromboplastin time4. And though these latter measurements can measure coagulation 
activity, they are poor predictors of HF16. Thus, there is a need for a diagnosis technique 
that is sensitive enough to detect ATC, quick enough to be applied in a point-of-care 
setting, and cheap enough to be widely available worldwide. 
In collaboration with Drs. Kamil Ekinci, Vural Kara and Emre Olceroglu (BU 
Mechanical Engineering), we explored whether adaptation of their silicon-based 
polydimethylsiloxane (PDMS) polymer microfluidics could fill such a role. The device, 
equipped with a continuous microchannel and several ports to access that channel, relies 
on measuring changes in electrical resistance to detect clot formation and lysis. 
Resistance is quantified by passing a constant electrical current through the solution and 
measuring the voltage. Since resistance is equivalent to voltage divided by current, and 
the current is kept constant, resistance and voltage are directly proportional. This concept 
has been explored briefly using capacitance rather than impedance to characterize 
coagulation17, although there are no applications to detect fibrinolysis. . Successful 
integration of this device could provide a way to rapidly, accurately, and inexpensively 
identify patients who may benefit from anti-fibrinolytic treatment following trauma. In 
order to screen conditions and identify initial coagulation factor concentrations 
appropriate for use in the microfluidics device, in vitro experiments were designed using 
turbidity measurements in a microplate reader to monitor clot formation and lysis.  	
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METHODS 
Turbidity Measurements 
  Measurements of changes in optical density at 405 nm (OD405) was used to 
determine turbidity of reaction solutions in a standard microplate reader (SpectraMax; 
Molecular Devices, Sunnyvale, CA). Human fibrinogen was obtained from Sigma-
Aldrich, human thrombin (alpha) and plasmin was obtained from Enzyme Research Labs 
(South Bend, IN). Fibrinogen was gel-filtered using PD-10 columns (Sigma-Aldrich) for 
buffer exchange, and stored in aliquots at -80°C. Additional freeze-thaw cycles were 
avoided. Thrombin and plasmin were aliquoted in 10-50µL aliquots and stored frozen at -
80°C. The enzymes were thawed rapidly, placed on ice during experimentation and 
discarded after use on the same day.  Protein concentrations were calculated based on 
absorbance at 280 nm (1cm) and the following: fibrinogen (MW 340 kDa; E1%=15.1); 
thrombin (MW 37 kDa; E1%=18.3); plasmin (83 kDa; E1%=17.0) 
 In wells of 96-well plate, reagent volumes to be added were calculated based on 
100 µL final volume. The buffer, either Tris-buffered saline (0.2 mM Tris, 0.15 M NaCl, 
pH 7.5;TBS) or TBS+0.1% w/v Gelatin (TBSG), was added first, followed by plasmin if 
necessary and then either fibrinogen (in thrombin-triggered experiments) or thrombin (in 
fibrinogen-triggered experiments). The final reagent, either fibrinogen or thrombin, was 
added last using a multichannel pipettor immediately before reading the plate in the 
spectrophotometer. The reaction setup is labeled for each figure. For the 37°C 
measurements, all reagents were warmed in a thermostatted water bath prior to using in 
wells. The plate was also placed in a 37°C incubator and microplate set to 37°C as well. 
	7 
Electrical Resistance Measurements 
The PDMS microfluidics device was made using a negative mold and then 
bonding to a glass slide as previously described22.  These devices were made in advance 
by collaborator Dr. Emre Olceroglu (post-doctoral fellow in Dr. Ekinci’s lab; BU 
Mechanical Engineering).  After completion, wells were created manually using a 3 mm 
biopsy punch. A pair of electrodes were placed into the wells of the device to provide 
current flow. The voltage was measured by a signal measuring device (e.g., an 
oscilloscope), and the fluctuation in voltage was monitored every 20 milliseconds for 10 
minutes. The signal measuring device was configured to display the amplitude of the 
signals over time. The voltage signals (mV) were processed via computer to permit 
analysis of slopes and amplitudes.   
 Several methodologic iterations were explored to identify optimal conditions and 
configurations of the microfluidics device that reproducibly and robustly reported clot 
formation (thrombin + fibrinogen) and clot lysis (thrombin + fibrinogen + plasmin). 
Premix Method 
 First thrombin (and plasmin if necessary) diluted in TBSG was added to a 
microcentrifuge tube. Then fibrinogen in TBSG was added to the same tube and the 
solution was pipetted up and down once to mix, while at the same time the voltage 
reading was started. Immediately the solution was added to the device until all the wells 
were full. The volume added varied depending on the device configuration.  
Non-premix Method 
 Thrombin diluted in TBSG was added directly to the device while the voltage 
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reading was active. Then, after voltage had stabilized, fibrinogen in TBSG was added to 
the device. 
Prewetting 
 In some cases, TBSG was added to the device while voltage reading was active. 
Upon stabilization of the voltage, the TBSG was removed by pipetting. This was done to 
ensure voltage reading and electrode setup was accurate prior to reaction initiation. 	 	
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RESULTS 
Turbidity  
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Fig 1 Effect of Starting Fibrinogen Concentration on Turbidity. TBS as buffer and thr 
addition to initiate reaction. Top: OD vs reaction time. Bottom: Maximum OD at 30 min 
vs fbg concentration. There is a direct correlation between the initial fbg concentration 
and the turbidity of solution after 30 minutes of reaction. 	  
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Fig 2 High vs Low Starting Fibrinogen Concentration on Turbidity. TBSG as buffer and 
fbg addition to initiate reaction. A: Low fbg concentration vs no thr control. B: High fbg 
concentration vs. no thr control. C: Low vs high fbg concentrations. D: Low vs high fbg 
concentrations in no thr controls. N=5.  	  
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Fig 3 Effect of Plasmin Concentration on Turbidity Change. TBS as buffer and thr 
addition to initiate reaction. Top: high fbg concentration. Bottom: low fbg concentration. 
The two reaction setups are identical except for the initial fbg concentration. Lower 
concentrations of plm seem to have little effect on the reaction. 	  
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Fig 4 Effect of Gelatin on Turbidity. Thr addition to initiate reaction. Top: TBS as buffer. 
Bottom: TBSG as buffer. The two reaction setups are identical except for the buffer used. 
Without gelatin, the presence of 36 nM plm and 72 nM plm had major effects on the OD 
curve compared to the no plm control, while the lower concentrations had minimal effect. 
With gelatin, the presence of 9 nM plm caused a similar major effect on the OD curve 
while the higher concentrations prevented coagulation altogether. Also worth noting that 
gelatin reduces the overall OD change for these reactions, but the relative amounts are 
still consistent.  	  
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Fig 5 Effect of Plasmin on Turbidity. TBSG as buffer and thr addition to initiate reaction. 
Without plm, the OD peaks in about 5 minutes and plateaus. In the presence of plm, there 
seems to be a much greater OD peak and in the two reactions with greater plm 
concentration, a decrease in OD following the peak. The higher the plm concentration, 
the earlier the decrease appears to occur. There is also an initial delay in OD rise seen in 
the reactions with plm. 	  
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Fig 6 Effect of Pre-Incubation Time. TBSG as buffer and thr addition to initiate reaction. 
Top: Ten minutes of pre-incubation between starting reagents allowed before thr added to 
initiate reaction. Bottom: Less than one minute of pre-incubation between starting 
reagents before thr addition. It was thought that the mixture of plm and fbg in the well 
could be reacting before thr was added and thus the time of pre-incubation affected the 
reaction curve. Thus this comparison was made between 10 minutes of pre-incubation 
and no deliberate pre-incubation before thr addition. An important difference seen is in 
the initial state of reaction. With 10 minutes of pre-incubation, the starting OD value 
seems to be quite different between the varying plm concentrations. Without pre-
incubation, these initial OD values are much closer together. 	  
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Fig 7 Effect of Plasmin Concentration on Lag Phase. TBSG as buffer and fbg addition to 
initiate reaction. Top: OD 405nm vs time. N=2. Bottom: Length of time of lag phase vs 
plm concentration. N=4. *** p<0.001; ** p<0.01. There is a highly reproducible effect of 
plm on the OD vs time curve in the presence of fbg and thr. The length of the lag phase, 
the delay before OD rises, is associated with the concentration of plm. 	  
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Fig 8 Plasmin Lag Phase Effect at 37°C. Demonstrating that an increase to body 
temperature from room temperature still results in a similar plasmin-induced effect of the 
increased lag phase and max OD. N=5 	  
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Resistance 
 
 
Fig 9 Major Design Iterations of PDMS Device. Dimensions not to scale. Black lines 
represent PDMS frame, blue lines represent continuous channel where fluid can travel 
freely. Circles represent opening wells where solution can be added. Top: Denoted X-
shaped model. Two adjacent wells on each side intersect with one end of the center 
channel. Bottom: Denoted Linear model. Five wells evenly spaced on a linear channel. 	  
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Fig 10 Comparison of Voltage Change in X-shaped vs Linear Designs. Representative 
data. Both designs prewet with TBSG, performed with premix method, and have final 
concentrations as titled. Top: X-shaped design. Sharp rise in first 40 seconds followed by 
slow decline over remainder of time. Bottom: Linear design (2 cm length). Sharp rise in 
first 10 seconds, then rate of change slows but remains positive over remainder of time. 	  
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Fig 11 Non-premix Method. Linear design (4 cm length). 40 uL of 4 nM Thr added to 
device first, then waited for voltage to stabilize. Then, at roughly t = 250 sec, 40 uL of 4 
mg/mL Fbg added. Final concentrations as titled. There is an unexpected rise in voltage 
when only thr is present which finally stabilizes after about 3 minutes. Upon addition of 
fbg, further increase in voltage is observed which plateaus after an additional 3 minutes. 
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Fig 12 Reproducibility of Linear Design. Each of 4 trials prewet with TBSG, 
performed with premix method, and have final concentrations as titled. Linear design (4 
cm length). Voltages normalized to initial values for each individual trial, therefore Y 
axis represents voltage change rather than absolute values. First 40 seconds excluded due 
to noise from pipetting solution to device. Rate constant (K) values, based on one-phase 
association regression analysis equation, are listed next to each trial (summarized in Fig 
14) 	  
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Fig 13 Reproducibility of Linear Design. Each trial performed with premix method, and 
have final concentrations as titled. Linear design (3 cm length). Voltages normalized to 
initial values for each trial, therefore Y axis represents voltage change rather than 
absolute voltage. Rate constant (K) values, based on the one-phase association regression 
equation, are listed next to each trial (summarized in Fig 14). 	  
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Fig 14 Summary of Rate Constants and Goodness of Fit. Error bars represent SEM. A: 
Rate constants. B: R2 values. 	  
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Fig 15 Incorporation of Plasmin into PDMS Device. Each trial performed with premix 
method, and have final concentrations as noted. Linear design (3 cm length). Voltages 
normalized to initial values for each trial, therefore Y axis represents voltage change 
rather than absolute voltage. 	  
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DISCUSSION 
 
 Based on Fig 1, we support that turbidity is a good measure of fibrin clot 
formation. While keeping the thrombin concentration constant, increasing the initial 
fibrinogen concentration causes an increase in maximum turbidity achievable. This is 
expected since fibrin clots are polymerous and increasing the available monomers should 
yield greater polymerization and thus greater turbidity, as is observed. It seems that this 
relationship is direct and linear after 30 minutes of reaction, but it should be noted that 
the two solutions with greater concentrations of fibrinogen have not reached their plateau 
in this time. Perhaps time to reach plateau is a better predictor of starting fibrinogen 
concentration than maximum turbidity. In Figs 2A and 2B, we further observe this 
occurrence using a control solution without thrombin to ensure that the observed change 
in turbidity is thrombin-fibrinogen specific. As expected there is no change in turbidity in 
the absence of thrombin. In Fig 2C we compare the turbidity change between initial 
fibrinogen concentrations of 1 mg/mL and 4 mg/mL. The two solutions have an almost 
identical rate of turbidity increase before they diverge after about two minutes of reaction 
time, where the 4 mg/mL sample continues its rate of increase and the 1 mg/mL sample 
begins to plateau. The initially identical rate of turbidity increase is expected because the 
reaction-catalyzing thrombin is saturated at either starting concentration of fibrinogen (1 
mg/mL fibrinogen is approximately 3 uM, a huge molar excess of the 4 nM thrombin). 
The divergence after two minutes is also expected since the lower concentration solution 
should begin to run out of available fibrinogen sooner than the greater concentration 
solution which maintains saturation levels for longer. Lastly, in Fig 2D, it is worth noting 
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that the constant turbidity detected in the control solutions without thrombin is slightly 
elevated in the higher fibrinogen concentration solution. 
In Fig 3, we observe the effect of adding plasmin to the reaction mixture. With 
both high and low concentrations of fibrinogen, there seems to be little effect on the 
initial rate of reaction until the plasmin concentration reaches 10 nM. In these solutions, 
the turbidity rise is slower but ultimately reaches a similar magnitude as the other 
solutions after 30 minutes of reaction. The cause of this effect is unclear. The most 
immediate explanation is that the fibrin polymer may be undergoing lysis by plasmin 
while it is being formed by thrombin and thus results in a diminished turbidity increase 
(the resulting FDPs are soluble and do not contribute to turbidity). Based on this 
explanation, one would also predict the turbidity to decrease again following its rise once 
fibrinogen was consumed, coagulation ceased, and fibrinolysis continued. This decrease, 
however, did not occur in the 30 minutes allotted for these measurements, and thus some 
experimental changes were made in order to observe lysis. 
In addition to increasing plasmin concentration to observe lysis, incorporation of 
gelatin into the buffer was proposed. Plasmin, in the absence (Fig 4 top) or presence (Fig 
4 bottom) of gelatin, can have a significant effect on the turbidity curve throughout the 
reaction. But the concentration required to observe this effect is much lower in the 
presence of gelatin. Without gelatin, the turbidity curve of reactions containing 9 nM and 
18 nM plasmin look fairly similar to the no plasmin control, while the greater plasmin 
concentrations of 36 nM and 72 nM result in drastically different curves. This same 
relative effect is seen in the presence of gelatin, albeit only in the 9 nM plasmin-
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containing solution. Plasmin concentrations greater than this prevented any increase in 
turbidity altogether. It appears that gelatin potentiates the effect of plasmin. This is likely 
due to its behavior as a carrier molecule, preventing the enzymes from getting trapped in 
microscopic imperfections in the plastic wells. Thus TBSG is used instead of TBS as the 
buffer in all experimental designs from this point forward. 
Now that lysis has been observed, we look at the specific effects plasmin has on 
the reaction. In Fig 5, we see a few distinct effects. First is that reactions with plasmin 
have a significantly greater maximum turbidity than those without, but the maximum 
value itself does not correlate with plasmin concentration. The greatest peak is from the 5 
nM plasmin reaction followed by the 10 nM and 2.5 nM plasmin reactions which have 
similar peaks. It is difficult to determine the cause of this effect. Second is that turbidity 
decline following the peak occurs earlier as plasmin concentration increases. The 10 nM 
plasmin reaction peaks at 7 minutes, the 5 nM plasmin reaction at 14 minutes, and the 2.5 
nM plasmin reaction has not yet begun to decline in the 30 minutes recorded. This is 
expected since more plasmin results in a higher rate of lysis and thus less time before a 
decrease in turbidity is observed. Third, and perhaps most interesting, is the initial delay 
in turbidity increase for the reactions containing plasmin. In the first two minutes, the rate 
of turbidity increase is greater in the no plasmin control than in the reactions containing 
plasmin. All three of these effects are consistent and reproducible, but it is the final one 
regarding this initial lag phase that we focus on.  
One possible explanation for the lag phase is that plasmin binds to fibrinogen in 
the well before thrombin is added to initiate the reaction, and the plasmin physically 
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hinders thrombin’s ability to cleave fibrinogen into fibrin. To explore this idea, we 
compared pre-incubation times of plasmin with fibrinogen before thrombin was added to 
start the reaction. Fig 6 top shows the result from 10 minutes of pre-incubation while Fig 
6 bottom shows the result with minimal pre-incubation. Both experimental designs follow 
similar trends: the 10 nM plasmin reactions reach the greatest turbidity and also have the 
longest lag phase; the 5 nM plasmin reactions have the second highest turbidity but do 
not reach their peak within the 10 minutes of reaction time, and the 1 nM plasmin 
reactions follow the no plasmin control closely. It seems, though, that the lag phase is 
extended with longer pre-incubation, especially in the 10 nM plasmin reactions. This 
supports the idea that plasmin and fibrinogen are having some interaction before the 
reaction is initiated with thrombin. To combat this and observe the lag phase without 
early plasmin-fibrinogen interaction, we changed the experiment design to have 
fibrinogen as the trigger. Instead, plasmin and thrombin will be present in the well and 
the reaction will begin once fibrinogen is added to the mixture. 
With this new order of reagents added, the turbidity remains almost exactly 
constant during the lag phase (Fig 7 top) and then rises quickly. We were able to establish 
a correlation between lag time and plasmin concentration (Fig 7 bottom). However, this 
association is not linear. The difference in lag time between the two lower plasmin 
concentration reactions and the no plasmin control is insignificant. However the 25 nM 
plasmin reaction has a significantly increased lag time and that of the 50 nM plasmin 
reaction is larger still. To be sure that this effect was consistent at body temperature, we 
repeated the experiment at 37°C using 50 nM plasmin against a no plasmin control (Fig 
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8). Two major differences between our room temperature experiments and our body 
temperature experiment are the magnitude of change in turbidity and the shorter time to 
reach maximum turbidity for the high plasmin sample. However the length of the lag 
phase was not affected by temperature and was consistent with our previous experiments. 
This lag phase is predicted to get continuously longer as the plasmin concentration 
increases until the plasmin concentration is high enough to prevent coagulation 
completely, as observed previously in Fig 4. Since we know that turbidity increases 
during protofibril aggregation and factor XIIIa ligation of D-regions, this lag phase must 
be due to the lack thereof. It therefore seems reasonable to believe that plasmin is 
interfering with protofibril aggregation and/or D-region ligation. 
In patients who are expected to have high levels of plasminogen activation 
following trauma, there is possibly a phenomenon occurring similar to that observed our 
in vitro experiments. We have shown that increased plasmin activity can cause a delay in 
fibrin clot formation and earlier lysis of the formed clot. And the effect seems to be 
particularly severe when reaching a certain threshold concentration of plasmin relative to 
fibrinogen. We know that only about forty percent of trauma patients suffer from ATC, 
so perhaps this fraction is representative of the patients who have developed a high 
enough level of active plasmin to cause this particularly severe HF. 
With the help of the PDMS microfluidics device, we can use electrical resistance 
(or proportionally, voltage) to monitor clot formation. Two designs, x-shaped and linear 
(Fig 9), have been considered. We found the linear design to be superior because the 
shape of the voltage vs time curve is closer to what is predicted based on single substrate-
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enzyme kinetics. This can be seen in Fig 10. The top graph is representative of the x-
shaped designs, which tend to have a small bump in voltage in the initial stage of the 
reaction followed by a slow but steady decline. The bottom graph is representative of the 
linear designs which have a gradual rise in voltage that approaches a plateau. Fig 11 
shows representative data of the non-premix method, where thrombin is added to the 
device first, followed by addition of fibrinogen to initiate reaction. The advantage of this 
method over the premix method is that the reaction is being measured when it is initiated. 
In the premix method, the reaction is initiated outside of the device and then added to it, 
and so the first moments of the reaction are missed. However a big disadvantage of the 
non-premix method is the inability to properly mix the reagents in the device, having to 
rely on diffusion. This results in a slow and incomplete reaction. For this reason it was 
decided that the premix method was better suited for measuring the reaction.  
Fig 12 shows the reaction voltage vs time curves for 4 different trials in a PDMS 
device. These curves were then fit with a one-phase substrate-enzyme association 
equation: 
y = y0 + (plateau – y0)(1-e-Kx) 
where y0 is the y-intercept, plateau is the maximum value reached, and K is the rate 
constant. The accuracy of this fit to the observed rise in voltage strongly supports the use 
of our device as a measurement of clot formation. The change in voltage over time is 
proportional to the predicted rise in product concentration in a reactant plus enzyme 
system. The rate constant is an important value to observe, as it is indicative of the rate of 
reaction, i.e. coagulation. Potentially, upon successful development and implementation 
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of the PDMS device, one could use this rate constant to determine if a patient has 
abnormal coagulation. However, there still remains some inconsistency in the rate 
constants we obtain. In Fig 12, trials A and B were two separate channels on the same 
PDMS device while trials C and D were two separate channels on another device. We can 
see that the rate constant for each device is fairly consistent, but there is some difference 
when comparing between devices. This is one necessary development before this concept 
can be applied to real life scenarios. The PDMS devices are currently made manually, so 
there are subtle but significant discrepancies between each one. Developing a method to 
automate their production would greatly improve the data consistency. Fig 13 looks at a 
shorter linear design, 3 cm, which we found to help reduce some subtle disparities 
between different PDMS devices such as the precise distance between two wells. The two 
trials shown are from two separate devices. This experiment was repeated to ensure 
consistency of rate constants (Fig 14A). Again, the curves are modeled closely by the 
one-phase association equation (Fig 14B), further supporting the use of resistance as a 
measure of clot formation. Thus, we can infer that addition of plasmin to this system 
should result in a similarly accurate measurement of fibrin clot formation and lysis, 
despite further complicating the system by introducing a second reaction step. 
We can see from Fig 15 that adding a high concentration of plasmin to the system, 
either 40 nM or 50 nM, inhibited the maximum resistance significantly, but the 25 nM 
plasmin did not have such a strong effect. This phenomenon is similar to what we have 
seen with the turbidity measurements, where the inhibitory effects of plasmin were 
minimal until reaching what seemed to be a threshold concentration. Further repetitions 
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of plasmin incorporation are necessary to evaluate the ability of the PDMS device to 
detect plasmin-induced effects.  
We conclude that, with continued development and design improvements of the 
PDMS microfluidics device, it can be useful for determining patient coagulation and 
fibrinolysis activity. Specifically, hyperfibrinolysis can be observed. The device is 
comparatively cheap when considering ROTEM and TEG devices as alternatives. It is 
small and can be used at point-of-care, and it only requires as much time as it takes for 
the blood sample to clot and lyse. And lastly they are cheap; each device is composed of 
less than five grams of PDMS. 
Furthermore, we believe the described plasmin-induced effect is a major 
contributor to the HF seen in ATC and additional studies need to be performed looking at 
early events of high plasmin coagulation systems. It is highly possible that excess 
plasmin activity causes a hindrance of protofibril aggregation and D-region ligation into a 
proper fibrin clot. Understanding the specific mechanisms in early clot formation and 
how they are affected by plasmin could unveil mysteries not only about ATC, but about 
coagulopathies in general.  
  
	37 
REFERENCES 
 
1. Brohi, K., Singh, J., Heron, M., & Coats, T. (2003). Acute Traumatic Coagulopathy: 
The Journal of Trauma: Injury, Infection, and Critical Care, 54(6), 1127–1130. 
https://doi.org/10.1097/01.TA.0000069184.82147.06 
 
2. Huber-Wagner, S., Lefering, R., Qvick, M., Kay, M. V., Paffrath, T., Mutschler, W., & 
Kanz, K.-G. (2007). Outcome in 757 severely injured patients with traumatic 
cardiorespiratory arrest. Resuscitation, 75(2), 276–285. 
https://doi.org/10.1016/j.resuscitation.2007.04.018 
 
3. Raza, I., Davenport, R., Rourke, C., Platton, S., Manson, J., Spoors, C., … Brohi, K. 
(2013). The incidence and magnitude of fibrinolytic activation in trauma patients. 
Journal of Thrombosis and Haemostasis, 11(2), 307–314. 
https://doi.org/10.1111/jth.12078 
 
4. Gall, L. S., Brohi, K., & Davenport, R. A. (2017). Diagnosis and Treatment of 
Hyperfibrinolysis in Trauma (A European Perspective). Seminars in Thrombosis and 
Hemostasis, 43(2), 224–234. https://doi.org/10.1055/s-0036-1598001 
 
5. Mosesson, M. W. (2005). Fibrinogen and fibrin structure and functions. Journal of 
Thrombosis and Haemostasis, 3(8), 1894–1904. https://doi.org/10.1111/j.1538-
7836.2005.01365.x 
 
6. Weisel, J. W., & Litvinov, R. I. (2013). Mechanisms of fibrin polymerization and 
clinical implications. Blood, 121(10), 1712–1719. https://doi.org/10.1182/blood-
2012-09-306639 
 
7. Litvinov, R. I., Gorkun, O. V., Owen, S. F., Shuman, H., & Weisel, J. W. (2005). 
Polymerization of fibrin: specificity, strength, and stability of knob-hole interactions 
studied at the single-molecule level. Blood, 106(9), 2944–2951. 
https://doi.org/10.1182/blood-2005-05-2039 
 
8. Fowler, W. E., Hantgan, R. R., Hermans, J., & Erickson, H. P. (1981). Structure of the 
fibrin protofibril. Proceedings of the National Academy of Sciences of the United 
States of America, 78(8), 4872–4876. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC320279/ 
 
9. Chernysh, I. N., Nagaswami, C., & Weisel, J. W. (2011). Visualization and 
identification of the structures formed during early stages of fibrin polymerization. 
Blood, 117(17), 4609–4614. https://doi.org/10.1182/blood-2010-07-297671 
 
	38 
11. Wolberg, A. S., & Campbell, R. A. (2008). Thrombin Generation, Fibrin Clot 
Formation and Hemostasis. Transfusion and Apheresis Science, 38(1), 15–23. 
https://doi.org/10.1016/j.transci.2007.12.005 
 
10. McKee, P. A., Mattock, P., & Hill, R. L. (1970). Subunit Structure of Human 
Fibrinogen, Soluble Fibrin, and Cross-Linked Insoluble Fibrin*. Proceedings of the 
National Academy of Sciences of the United States of America, 66(3), 738–744. 
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283112/ 
 
12. Bouma, B., Maas, C., Hazenberg, B. P. C., Lokhorst, H. M., & Gebbink, M. F. B. G. 
(2007). Increased plasmin-α2-antiplasmin levels indicate activation of the 
fibrinolytic system in systemic amyloidoses. Journal of Thrombosis and 
Haemostasis, 5(6), 1139–1142. https://doi.org/10.1111/j.1538-7836.2007.02457.x 
 
14. da Luz, L. T., Nascimento, B., & Rizoli, S. (2013). Thrombelastography (TEG®): 
practical considerations on its clinical use in trauma resuscitation. Scandinavian 
Journal of Trauma, Resuscitation and Emergency Medicine, 21, 29. 
https://doi.org/10.1186/1757-7241-21-29 
 
15. Jackson, G. N. B., Ashpole, K. J., & Yentis, S. M. (2009). The TEG® vs the 
ROTEM® thromboelastography/thromboelastometry systems. Anaesthesia, 64(2), 
212–215. https://doi.org/10.1111/j.1365-2044.2008.05752.x 
 
16. Harris, N. S., Bazydlo, L. A., & Winter, W. E. (2012, January). Coagulation Tests - A 
Primer on Hemostasis for Clinical Chemists. Retrieved November 3, 2017, from 
https://www.aacc.org/publications/cln/articles/2012/january/coagulation-tests 
 
17. Lei, K. F., Chen, K.-H., Tsui, P.-H., & Tsang, N.-M. (2013). Real-Time Electrical 
Impedimetric Monitoring of Blood Coagulation Process under Temperature and 
Hematocrit Variations Conducted in a Microfluidic Chip. PLoS One, 8(10), e76243. 
https://doi.org/10.1371/journal.pone.0076243 
 
18. Enderson, B. L., Chen, J. P. P., Robinson, R. B., & Maull, K. I. (1991). Fibrinolysis 
in Multisystem Trauma Patients. Journal of Trauma-Injury Infection, 31(9), 1240–
1246. 
 
19. Moore, E. E., Moore, H. B., Gonzalez, E., Sauaia, A., Banerjee, A., & Silliman, C. C. 
(2016a). Rationale for the selective administration of tranexamic acid to inhibit 
fibrinolysis in the severely injured patient. Transfusion, 56, S110–S114. 
https://doi.org/10.1111/trf.13486 
 
20. Sauaia, A., Moore, F. A., Moore, E. E., Moser, K. S., Brennan, R., Read, R. A., & 
Pons, P. T. (n.d.). Epidemiology of trauma deaths: a reassessment. The Journal of 
	39 
Trauma, 38(2), 185–193. Retrieved from 
https://insights.ovid.com/pubmed?pmid=7869433 
 
21. Schöchl, H., Frietsch, T., Pavelka, M., & Jámbor, C. (2009). Hyperfibrinolysis After 
Major Trauma: Differential Diagnosis of Lysis Patterns and Prognostic Value of 
Thrombelastometry. The Journal of Trauma: Injury, Infection, and Critical Care, 
67(1), 125–131. https://doi.org/10.1097/TA.0b013e31818b2483 
 
22. Friend, J., & Yeo, L. (2010). Fabrication of microfluidic devices using 
polydimethylsiloxane. Biomicrofluidics, 4(2). https://doi.org/10.1063/1.3259624 
  
	40 
CURRICULUM VITAE 
